Dicerna Pharmaceuticals Inc (DRNA) Receives $8.50 Average Price Target from Brokerages
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $8.50.
DRNA has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. HC Wainwright restated a “buy” rating and set a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Finally, ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 2nd.
In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were bought at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 29.41% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Deschutes Portfolio Strategy LLC acquired a new position in Dicerna Pharmaceuticals in the 3rd quarter worth approximately $575,000. Palo Alto Investors LLC boosted its position in Dicerna Pharmaceuticals by 4.0% in the 2nd quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after purchasing an additional 19,394 shares in the last quarter. Birchview Capital LP boosted its position in Dicerna Pharmaceuticals by 125.0% in the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after purchasing an additional 25,000 shares in the last quarter. Renaissance Technologies LLC boosted its position in Dicerna Pharmaceuticals by 2.4% in the 1st quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock worth $1,423,000 after purchasing an additional 9,818 shares in the last quarter. Finally, EcoR1 Capital LLC boosted its position in Dicerna Pharmaceuticals by 101.0% in the 2nd quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock worth $2,435,000 after purchasing an additional 385,992 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.
Dicerna Pharmaceuticals (NASDAQ:DRNA) traded down $0.26 on Monday, hitting $8.37. 368,957 shares of the stock traded hands, compared to its average volume of 267,355. Dicerna Pharmaceuticals has a 12-month low of $2.42 and a 12-month high of $10.24. The firm has a market capitalization of $169.24, a P/E ratio of -2.44 and a beta of 2.84.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The company had revenue of $0.47 million for the quarter. During the same quarter in the prior year, the business posted ($0.68) EPS. The firm’s quarterly revenue was up 192.6% on a year-over-year basis. sell-side analysts forecast that Dicerna Pharmaceuticals will post -3.04 earnings per share for the current fiscal year.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.